Table I.

Intratumoral SLC administration promotes Th1 cytokine and antiangiogenic chemokine release and a decline in immunosuppressive mediatorsa

GroupsPGE2VEGFIFN-γGM-CSFIL-10IL-12TGF-βMIGIP-10
3LL+ diluent28,510 ± 400757 ± 26104 ± 15<5244 ± 4024 ± 65,820 ± 5781,000 ± 20015,100 ± 1,100
3LL+ SLC8,737 ± 210*222 ± 34*549 ± 16*56 ± 11112 ± 13*42 ± 1*2,473 ± 26*6,600 ± 100*39,400 ± 2,300*
  • a Cytokine profiles in tumors were determined in mice treated intratumorally with SLC and compared with those in diluent-treated control mice bearing tumors. Nonnecrotic tumors were harvested, cut into small pieces, and passed through a sieve. Tumors were evaluated for the presence of IL-10, IL-12, GM-CSF, IFN-γ, TGF-β, VEGF, MIG, and IP-10 by ELISA and for PGE2 by EIA in the supernatants after overnight culture. Cytokine, PGE2, and VEGF determinations from the tumors were corrected for total protein by Bradford assay. Results are expressed as picograms per milligram total protein/24 h. Compared with tumor nodules from diluent-treated tumor-bearing controls, mice treated intratumorally with SLC had significant reductions of PGE2, VEGF, IL-10, and TGF-β but an increase in IFN-γ, GM-CSF, IL-12, MIG, and IP-10. Experiments were repeated twice.

  • b , p < 0.01 compared with diluent-treated tumor-bearing mice, n = 6 mice/group.